Who We Are
Paul Resnik, CFA
Director of Research and Senior Research Analyst
Mr. Resnik is a Chartered Financial Analyst and Registered Supervisory Analyst with over 40 years of research and management experience. Prior to co-founding Uncommon Equities, he served as Director of Research, Supervisory Analyst and Chief Market Strategist for several independent research and brokerage firms. At Shearson Lehman Brothers, Mr. Resnik advised equity research analysts as a member of the Lehman Brothers Equity Research Department Investment Policy Committee. He was Director of Equity Research Marketing at E.F. Hutton and also served in research capacities at Paine Webber and Merrill Lynch. Mr. Resnik is the President of Resnik Asset Management Co., Inc, a registered investment advisor, which has been managing large cap equity portfolios for high net worth investors since 1995. Mr. Resnik graduated from Hobart College with a Bachelor of Arts in Economics. He is a member of the CFA Institute.
Senior Research Analyst
Ms. Resnik co-founded Uncommon Equities to provide professional independent research on a cost-effective platform for emerging publicly-traded companies. Ms. Resnik principally conducts financial analysis of emerging, biotech companies capitalizing on her extensive consulting career in the pharmaceutical industry. Her industry experience spans both large global pharmaceutical companies and smaller biotech companies in the areas of new drug development and clinical research education. Ms. Resnik holds a Bachelor of Arts degree in Biology from Clark University and a Masters of Science degree in Pharmacology from Northeastern University.
Uncommon Equities sends press releases to announce publication of initial research reports and updates to:
- Dow Jones
- Thompson Reuters
- ABC News
- Associated Press
- CNN Money
and hundreds of national and regional print, radio and television outlets
Based on the projected change in share price from current price to projected target price plus projected dividend yield, we believe the shares can provide a total return of over 20% over the next 12 months.
Based on the projected change in share price from current price to projected target price plus projected dividend yield, we believe the shares can provide a total return of over 20% over the next 12 months. However, in light of short operating histories, dependence on new initiatives or products, and/or the need for external financing, we believe the shares should only be considered by investors for which speculative securities are appropriate.
We take a neutral view of the stock 12-months out and, based on this time horizon, do not maintain either a Buy or Sell recommendation.
Based on the projected change in share price from current price to projected target price plus projected dividend yield, we believe the shares will have a negative return over the next 12 months.